Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, Non-Hodgkin × AZD5153 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Breast Neoplasms 1

Interventions

Rituximab 181 Cyclophosphamide 161 Etoposide 80 Peripheral Blood Stem Cell Transplantation 77 fludarabine phosphate 74 Filgrastim 73 Melphalan 56 Vincristine 55 Whole-Body Irradiation 52 Mycophenolic Acid 50 Busulfan 50 Radiotherapy 45 Doxorubicin 45 Cytarabine 45 Cyclosporine 43 fludarabine 42 Prednisone 42 Tacrolimus 40 Granulocyte Colony-Stimulating Factor 40 Methotrexate 37 Bendamustine Hydrochloride 35 Dexamethasone 30 Carmustine 30 Antilymphocyte Serum 29 Gemcitabine 24 Bortezomib 22 ibritumomab tiuxetan 21 Stem Cell Transplantation 20 venetoclax 19 Methylprednisolone 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03527147 2022-08-15

PRISM

Acerta Pharma BV

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡